ASMB (Assembly Biosciences) ROC %: -109.64% (As of Mar. 2026)


ASMB Assembly Biosciences Inc ASMB
32 GF Score
Price $26.74
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences ROC %?

Assembly Biosciences ASMB +10.25% 32 ROC % is -109.64% as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Assembly Biosciences's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -109.64%.

As of today (2026-06-27), Assembly Biosciences's WACC % is 11.51%. Assembly Biosciences's ROC % is -29.63% (calculated using TTM income statement data). Assembly Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Assembly Biosciences  (NAS:ASMB) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Assembly Biosciences's WACC % is 11.51%. Assembly Biosciences's ROC % is -29.63% (calculated using TTM income statement data). Assembly Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Assembly Biosciences ROC % Related Terms


Assembly Biosciences ROC % Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences ROC % Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -154.50 -309.32 -234.76 -102.20 -25.18

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.81 -93.94 -87.98 159.69 -109.64
ASMB
32GF Score
Assembly Biosciences Inc ASMB
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences ROC % Calculation

Assembly Biosciences's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-12.118 * ( 1 - 0% )/( (48.226 + 48.037)/ 2 )
=-12.118/48.1315
=-25.18 %

where

Assembly Biosciences's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-45.48 * ( 1 - 0% )/( (48.037 + 34.926)/ 2 )
=-45.48/41.4815
=-109.64 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -109.64% mean?
Assembly Biosciences (ASMB) has a ROC % of -109.64% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' ROC % too high?
Assembly Biosciences' current ROC % is -109.64%. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' ROC % compare to MDXG and AGMB?
Assembly Biosciences' ROC % of -109.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current ROC % is -109.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current ROC % of -109.64%. The current ROC % is -109.64%. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current ROC % is -109.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score

Get the complete analysis for ASMB

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.74
Price